• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Head of Group Finance Blair Graeme

    2/27/25 8:50:48 PM ET
    $IOSP
    Major Chemicals
    Industrials
    Get the next $IOSP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Blair Graeme

    (Last) (First) (Middle)
    8310 SOUTH VALLEY HIGHWAY
    SUITE 350

    (Street)
    ENGLEWOOD CO 80112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INNOSPEC INC. [ IOSP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Head of Group Finance
    3. Date of Earliest Transaction (Month/Day/Year)
    02/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Phantom Stock (1) 02/24/2025 A 300 02/24/2028 02/24/2028 Common Stock 300 $0 300 D
    Explanation of Responses:
    1. Each share of phantom stock is the economic equivalent of one share of Innospec common stock. The award is settled in cash on the Expiration Date based on the closing price of Innospec stock on that date.
    Graeme Blair 02/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IOSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOSP

    DatePrice TargetRatingAnalyst
    4/21/2025$115.00Neutral → Buy
    Seaport Research Partners
    3/30/2022Neutral
    Seaport Research Partners
    More analyst ratings

    $IOSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Innospec upgraded by Seaport Research Partners with a new price target

      Seaport Research Partners upgraded Innospec from Neutral to Buy and set a new price target of $115.00

      4/21/25 8:30:53 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • Seaport Research Partners initiated coverage on Innospec

      Seaport Research Partners initiated coverage of Innospec with a rating of Neutral

      3/30/22 7:37:48 AM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parrette Leslie J sold $40,421 worth of shares (446 units at $90.63), decreasing direct ownership by 8% to 5,497 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:11:51 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SVP, HUMAN RESOURCES Griffin Hardy Louis Iii covered exercise/tax liability with 600 shares, decreasing direct ownership by 8% to 6,742 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:05:37 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SVP, Corporate Dev and IR Barnes Corbin covered exercise/tax liability with 740 shares, decreasing direct ownership by 8% to 8,998 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:01:11 PM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parrette Leslie J bought $15,135 worth of shares (143 units at $105.84), increasing direct ownership by 3% to 4,734 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      8/14/24 6:31:38 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Parrette Leslie J bought $24,867 worth of shares (189 units at $131.57), increasing direct ownership by 4% to 4,591 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/20/24 6:07:17 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Parrette Leslie J bought $50,824 worth of shares (410 units at $123.96), increasing direct ownership by 13% to 3,620 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      2/23/24 6:19:14 PM ET
      $IOSP
      Major Chemicals
      Industrials